FrancophonIA/ELRC3.0 huggingface dataset:
English: Dalbavancin MICs are higher for vancomycin-intermediate staphylococci (VISA) than for fully vancomycin susceptible strains.
Croatian: MIK vrijednosti dalbavancina više su za stafilokoke umjereno osjetljive na vankomicin (VISA) nego za sojeve potpuno osjetljive na vankomicin.
English: Increase in blood levels of gamma-glutamyl transferase (an enzyme produced by the liver and other body tissues)
Croatian: • Porast razine gama-glutamil transferaze u krvi (enzima koji se proizvodi u jetri i drugim tkivima)
English: Xydalba contains the active substance dalbavancin, which is an antibiotic of the glycopeptide group.
Croatian: Xydalba sadrži djelatnu tvar dalbavancin koji je antibiotik iz skupine glikopeptida.
English: Clinical efficacy has not been established against the following pathogens although in vitro studies suggest that they would be susceptible to dalbavancin in the absence of acquired mechanisms of resistance:
Croatian: Klinička djelotvornost nije ustanovljena protiv sljedećih patogena iako in vitro ispitivanja upućuju na to da su možda osjetljivi na dalbavancin u odsustvu stečenih mehanizama rezistencije:
English: Following administration of a single 1,000 mg dose in healthy subjects, an average of 19 % to 33 % of the administered dalbavancin dose was excreted in urine as dalbavancin and 8 % to 12 % as the metabolite hydroxy-dalbavancin.
Croatian: Nakon primjene jednokratne doze od 1000 mg zdravim ispitanicima, prosječno je 19 % do 33 % primijenjene doze dalbavancina izlučeno u urinu u obliku dalbavancina, a 8 % do 12 % u obliku metabolita hidroksidalbavancina.
English: 3 1,500 mg; Study DUR001-303 subjects with evaluable PK sample.
Croatian: 3 1500 mg; Studija DUR001-303 subjekta s PK uzorkom koji je bilo moguće ocijeniti.
English: Dalbavancin is a bactericidal lipoglycopeptide.
Croatian: Dalbavancin je baktericidni lipoglikopeptid.
English: The safety and efficacy of Xydalba in children aged from birth to < 18 years have not yet been established.
Croatian: Sigurnost i djelotvornost Xydalbe u djece u dobi od rođenja do < 18 godina još nije ustanovljena.
English: The clinical significance of the decrease in mean plasma CLT, and the associated increase in AUC0-∞ noted in these pharmacokinetic studies of dalbavancin in subjects with severe renal impairment has not been established.
Croatian: Klinički značaj smanjenja srednje vrijednosti CLT u plazmi i povezano povećanje AUC0-∞ uočeno u ovim farmakokinetičkim ispitivanjima dalbavancina u ispitanika s teškim oštećenjem bubrega nije ustanovljen.
English: Hydroxy-dalbavancin and mannosyl aglycone show significantly less antibacterial activity compared to dalbavancin.
Croatian: Hidroksidalbavancin i manozil aglikon pokazali su značajno manju antibakterijsku aktivnost u usporedbi s dalbavancinom.
English: Psychiatric disorders insomnia
Croatian: Psihijatrijski poremećaji nesanica
English: No specific information is available on the treatment of overdose with dalbavancin, as dose-limiting toxicity has not been observed in clinical studies.
Croatian: Nisu dostupne specifične informacije o liječenju predoziranja dalbavancinom jer toksičnost koja ograničava dozu nije uočena u kliničkim ispitivanjima.
English: Rapid intravenous infusions of glycopeptide antibacterial agents can cause reactions that resemble “Red-Man Syndrome”, including flushing of the upper body, urticaria, pruritus, and/or rash.
Croatian: Brze intravenske infuzije glikopeptidnih antibakterijskih lijekova mogu uzrokovati reakcije koji sliče „sindromu crvenog čovjeka“, uključujući navale crvenila u gornjem dijelu tijela, urtikariju, svrbež i/ili osip.
English: What Xydalba is and what it is used for What you need to know before you are given Xydalba How you will be given Xydalba Possible side effects
Croatian: Što je Xydalba i za što se koristi Što morate znati prije nego primite Xydalbu
English: Dalbavancin was not mutagenic or clastogenic in a battery of in vitro and in vivo genotoxicity tests.
Croatian: Dalbavancin nije bio mutagen niti klastogen u seriji in vitro i in vivo testova genotoksičnosti.
English: Warnings and precautions Talk to your doctor, pharmacist or nurse before being given Xydalba:
Croatian: Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego primite Xydalbu:
English: No dose adjustment of dalbavancin is recommended for patients with mild hepatic impairment (Child-Pugh A).
Croatian: Nije potrebno prilagođavanje doze dalbavancina za bolesnike s blagim oštećenjem jetre (Child-Pugh A).
English: The use of antibiotics may promote the overgrowth of non-susceptible micro-organisms.
Croatian: Organizmi koji nisu osjetljivi na lijek Primjena antibiotika može potaknuti prekomjerni rast mikroorganizama koji nisu osjetljivi na lijek.
English: Potential for dalbavancin to affect the pharmacokinetics of other medicinal products.
Croatian: Potencijal utjecaja dalbavancina na farmakokinetiku drugih lijekova.
English: Xydalba is for single use only.
Croatian: Xydalba je samo za jednokratnu uporabu.
English: In rats, at exposures approximately 3 times above clinical exposure, there was reduced fertility and an increased incidence of embryo-lethality, reductions in foetal weight and skeletal ossification and increased neonatal mortality.
Croatian: U štakora, pri izloženosti otprilike 3 puta većoj od kliničke izloženosti, uočena je smanjena plodnost i povećana incidencija smrtnosti zametka, smanjenje težine ploda i osifikacije skeleta i povećana smrtnost novorođenih.
English: In rabbits, abortion occurred in conjunction with maternal toxicity at exposures below the human therapeutic range.
Croatian: Kod kunića je došlo do pobačaja zajedno s toksičnosti za majku pri izloženostima ispod ljudskog terapijskog raspona.
English: The safety and efficacy of dalbavancin in children aged from birth to < 18 years has not yet been established.
Croatian: Sigurnost i djelotvornost dalbavancina u djece u dobi od rođenja do < 18 godina još nije ustanovljena.
English: Apparent terminal t½ was similar for dalbavancin doses of 1,000 mg and 15 mg/kg, with mean values of 227 and 202 hours, respectively.
Croatian: Prividni terminalni t½ bio je sličan za doze dalbavancina od 1000 mg i 15 mg/kg, sa srednjim vrijednostima od 227 odnosno 202 sata.
English: The pharmacokinetics of dalbavancin were evaluated in 28 subjects with varying degrees of renal impairment and in 15 matched control subjects with normal renal function.
Croatian: Farmakokinetika dalbavancina procijenjena je na 28 ispitanika s različitim stupnjevima oštećenja bubrega i na 15 podudarnih kontrolnih ispitanika s normalnom funkcijom bubrega.
English: Interactions with other antibacterial agents
Croatian: Interakcije s drugim antibakterijskim lijekovima
English: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, so it is essentially ‘sodium- free'.
Croatian: Ovaj lijek sadrži manje od 1 mmol natrija (23 mg) po dozi, tj. zanemarive količine natrija.
English: The mean AUC for subjects with creatinine clearance < 30 ml/min was approximately 2 - fold higher.
Croatian: Srednja vrijednost AUC u ispitanika s klirensom kreatinina < 30 ml/min je bila otprilike dvaput veća.
English: Dose adjustments are not required for patients with mild or moderate renal impairment (creatinine clearance ≥ 30 to 79 ml/min).
Croatian: Nije potrebno prilagođavanje doze za bolesnike s blagim ili umjerenim oštećenjem bubrega (klirens kreatinina ≥ 30 do 79 ml/min).
English: In such circumstance, the discontinuation of dalbavancin and the use of supportive measures together with the administration of specific treatment for Clostridioides (formerly Clostridium) difficile should be considered.
Croatian: U takvim okolnostima, potrebno je razmotriti prestanak primjene dalbavancina i primjenu potpornih mjera zajedno s primjenom specifičnog liječenja za Clostridioides
English: The metabolites hydroxy-dalbavancin and mannosyl aglycone have been detected in urine (< 25 % of administered dose).
Croatian: Metaboliti hidroksidalbavancin i manozil aglikon otkriveni su u mokraći (< 25 % od primijenjene doze).
English: Clearance and volume of distribution at steady state are comparable between healthy subjects and patients with infections.
Croatian: Klirens i volumen distribucije u stanju dinamičke ravnoteže usporedivi su između zdravih ispitanika i bolesnika s infekcijom.
English: After dilution the solution for infusion must have a final concentration of 1 to 5 mg/ml dalbavancin
Croatian: Razrijeđena otopina za infuziju mora imati konačnu koncentraciju od 1 do 5 mg/ml dalbavancina
English: How to store Xydalba
Croatian: Kako čuvati Xydalbu
English: Reproductive system and breast disorders vulvovaginal pruritus
Croatian: Poremećaji reproduktivnog sustava i dojki vulvovaginalni pruritus
English: Dalbavancin should be administered with caution in patients known to be hypersensitive to other glycopeptides since cross-hypersensitivity may occur.
Croatian: Reakcije preosjetljivosti Dalbavancin je potrebno primjenjivati s oprezom u bolesnika s poznatom preosjetljivosti na ostale glikopeptide jer može doći do križne preosjetljivosti.
English: Potential for other medicinal products to affect the pharmacokinetics of dalbavancin.
Croatian: Potencijal utjecaja drugih lijekova na farmakokinetiku dalbavancina.
English: Dalbavancin pharmacokinetics in subjects with end-stage renal disease receiving regularly scheduled renal dialysis (3 times/week) were similar to those observed in subjects with mild to moderate renal impairment, and less than 6 % of an administered dose is removed after 3 hours of haemodialysis.
Croatian: Farmakokinetika dalbavancina u ispitanika u završnom stadiju bolesti bubrega koji redovito primaju hemodijalizu (3 puta tjedno) bila je slična onoj uočenoj u ispitanika s blagim do umjerenim oštećenjem bubrega, te se manje od 6 % primijenjene doze ukloni nakon 3 sata hemodijalize.
English: If you suffer from chronic kidney problems, your doctor may decide to reduce your dose.
Croatian: Ako imate kronične bubrežne tegobe, vaš liječnik može odlučiti smanjiti Vašu dozu lijeka.
English: Based on simulations, dose adjustment is needed for patients with chronic renal impairment whose creatinine clearance is < 30 ml/min and who are not receiving regular haemodialysis (see sections 4.2 and 5.2).
Croatian: Na temelju simulacija, potrebno je prilagođavanje doze za bolesnike s kroničnim oštećenjem bubrega čiji je klirens kreatinina < 30 ml/min i koji ne primaju redovitu hemodijalizu (vidjeti dijelove 4.2 i 5.2).
English: The prepared Xydalba solution for infusion must not be used if there are any particles or the solution is cloudy.
Croatian: Pripremljena Xydalba otopina za infuziju ne smije se koristiti ako su vidljive bilo kakve čestice ili je otopina zamućena.
English: Dose adjustments are not required for patients receiving regularly scheduled haemodialysis (3 times/week), and dalbavancin may be administered without regard to the timing of haemodialysis.
Croatian: Nije potrebno prilagođavanje doze za bolesnike koji redovito primaju hemodijalizu (3 puta u tjednu) i dalbavancin se može davati bez obzira na vrijeme primanja hemodijalize.
English: Xydalba is given in a single dose of 1,500 mg or in two doses a week apart: 1,000 mg on Day 1 and 500 mg on Day 8.
Croatian: Xydalba se primjenjuje kao jednokratna doza od 1500 mg ili u dvije doze u razmaku od tjedan dana: 1000 mg na Dan 1 i 500 mg na Dan 8.
English: Although no information is available specifically regarding the use of haemodialysis to treat overdose, it should be noted that in a Phase 1 study in patients with renal impairment, less than 6 % of the recommended dalbavancin dose was removed after 3 hours of haemodialysis.
Croatian: Iako ciljani podaci u vezi primjene hemodijalize za liječenje predoziranja nisu dostupni, potrebno je napomenuti da je u ispitivanju faze 1 kod bolesnika s oštećenjem bubrega hemodijalizom u roku od 3 sata uklonjeno manje od 6 % preporučene doze dalbavancina.
English: For example: 25 ml of the concentrate contains 500 mg dalbavancin.
Croatian: Npr.: 25 ml koncentrata sadrži 500 mg dalbavancina.
English: The use of Xydalba in children under 18 has not yet been studied.
Croatian: Primjena Xydalbe u djece mlađe od 18 godina nije ispitivana.
English: No accumulation of dalbavancin was observed following multiple intravenous infusions administered once-weekly for up to 8 weeks (1,000 mg on Day 1, followed by up to 7 weekly 500 mg doses) in healthy adults.
Croatian: Nije primijećena akumulacija dalbavancina nakon višestrukih intravenskih infuzija primijenjenih jednom tjedno u trajanju do 8 tjedana (1000 mg prvi dan, nakon čega je slijedilo do 7 tjednih doza od 500 mg) kod zdravih odraslih osoba.
English: Following a single intravenous dose of 1,000 mg in healthy volunteers AUC in skin blister fluid amounted (bound and unbound dalbavancin) to approximately 60 % of the plasma AUC at day 7 post-dose.
Croatian: 1000 mg u zdravih dobrovoljaca AUC u tekućini u mjehurićima na koži (vezani i nevezani dalbavancin) iznosio je oko 60 % AUC-a plazme 7. dan nakon primjene doze.
English: The pharmacokinetics of dalbavancin were evaluated in 17 subjects with mild, moderate, or severe hepatic impairment and compared to 9 matched healthy subjects with normal hepatic function.
Croatian: Farmakokinetika dalbavancina procijenjena je na 17 ispitanika s blagim, umjerenim ili teškim oštećenjem jetre i uspoređena je s 9 podudarnih zdravih ispitanika s normalnom funkcijom jetre.
English: The European Medicines Agency has deferred the obligation to submit the results of studies with Xydalba in one or more subsets of the paediatric population in ABSSSI (see sections 4.2 and 5.2 for information on paediatric use).
Croatian: Europska agencija za lijekove je odgodila obvezu podnošenja rezultata ispitivanja lijeka Xydalba u jednoj ili više podskupina pedijatrijske populacije u akutnim bakterijskim infekcijama kože i kožnih struktura (vidjeti dijelove 4.2 i 5.2 za informacije o pedijatrijskoj primjeni).
English: The interaction potential of dalbavancin on medicinal products metabolised by CYP enzymes is expected to be low since it is neither an inhibitor nor an inducer of CYP enzymes in vitro.
Croatian: Očekuje se nizak potencijal interakcije dalbavancina s lijekovima koji se metaboliziraju putem enzima CYP jer dalbavancin nije ni inhibitor ni induktor enzima CYP in vitro.
English: Patients with chronic kidney problems
Croatian: Bolesnici s kroničnim bubrežnim tegobama
English: If a common intravenous line is being used to administer other medicinal products in addition to Xydalba, the line should be flushed before and after each Xydalba infusion with 5% glucose solution for infusion.
Croatian: Ako se ista infuzijska linija koristi i za primjenu drugih lijekova uz lijek Xydalba, prije i nakon svake primjene Xydalbe liniju je potrebno isprati 5%-tnom otopinom glukoze za infuziju.
English: In dogs only, infusion reactions characterised by skin swelling and/or redness (not associated with the injection site), mucosal pallor, salivation, vomiting, sedation, and modest declines in blood pressure and increases in heart rate were observed in a dose-dependent manner.
Croatian: Samo u pasa primijećene su reakcije na infuziju karakterizirane oticanjem kože i/ili crvenilom (nepovezanim s mjestom primjene), bljedilom sluznice, salivacijom, povraćanjem, sedacijom i umjerenim padom krvnog tlaka te porastom srčane frekvencije ovisno o dozi.
English: 2 1,000 mg on Day 1 + 500 mg on Day 8; Study DUR001-303 subjects with evaluable PK sample.
Croatian: 2 1000 mg 1. dan + 500 mg 8. dan; Studija DUR001-303 subjekta s PK uzorkom koji je bilo moguće ocijeniti.
English: The solution for infusion must be clear, colourless to yellow solution with no visible particles.
Croatian: Otopina za infuziju mora biti bistra, bezbojna do žuta otopina bez vidljivih čestica.
English: Investigations blood lactate dehydrogenase increased, alanine aminotransferase increased,
Croatian: Pretrage povišena laktatdehidrogenaza u krvi, povišena alanin aminotransferaza, povišena aspartat aminotransferaza,
English: Blood and lymphatic system disorders anaemia, thrombocytosis, eosinophilia, leucopenia, neutropenia
Croatian: Poremećaji krvi i limfnog sustava anemija, trombocitoza, eozinofilija, leukopenija, neutropenija
English: There are no data from the use of dalbavancin in pregnant women.
Croatian: Nema podataka o primjeni dalbavancina u trudnica.
English: Rare aspartate aminotransferase increased, blood uric acid increased, liver function test abnormal, transaminases increased, blood alkaline phosphatase increased, platelet count increased, body temperature increased, hepatic enzyme increased, gamma-glutamyl transferase increased,
Croatian: povišena mokraćna kiselina u krvi, poremećeni testovi funkcije jetre, povišene transaminaze, povišena alkalna fosfataza u krvi, povećan broj trombocita, povišena tjelesna temperatura, povišeni jetreni enzimi, povišena gama-glutamil transferaza,
English: (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000).
Croatian: rijetko (≥ 1/10 000 i < 1/1000).
English: Frequency categories are derived according to the following conventions: very common (≥ 1/10), common
Croatian: Kategorije učestalosti proizlaze iz sljedeće konvencije: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100),
English: Xydalba powder for concentrate for solution for infusion is provided in a 48 ml glass vial with a green flip off seal.
Croatian: Xydalba prašak za koncentrat za otopinu za infuziju dolazi u staklenoj bočici od 48 ml sa zelenim flip-off zatvaračem.
English: Following a single dose of 500 mg or 1,000 mg dalbavancin, the mean plasma clearance (CLT) was reduced 11 %, 35 %, and 47 % in subjects with mild (CLCR 50 - 79 ml/min), moderate (CLCR 30 - 49 ml/min), and severe (CLCR < 30 ml/min) renal impairment, respectively, compared to subjects with normal renal function.
Croatian: Nakon jednokratne doze od 500 mg ili 1000 mg dalbavancina, srednja vrijednost klirensa u plazmi (CLT) smanjena je 11 %, 35 %, i 47 % u ispitanika s blagim (CLCR 50 - 79 ml/min), umjerenim (CLCR 30 - 49 ml/min)
English: The most common adverse reactions occurring in ≥ 1 % of patients treated with dalbavancin were nausea (2.4 %), diarrhoea (1.9 %), and headache (1.3 %) and were generally of mild or moderate severity.
Croatian: (2,4 %), proljev (1,9 %) i glavobolja (1,3 %), te su uglavnom bile blage ili umjerene težine.
English: Antibacterial-associated colitis and pseudomembranous colitis have been reported with the use of nearly all antibiotics and may range in severity from mild to life threatening.
Croatian: Kolitis i pseudomembranozni kolitis povezani s antibakterijskim lijekovima prijavljeni su pri primjeni gotovo svih antibiotika te mogu varirati u težini od blagih do po život opasnih.
English: Xydalba contains sodium
Croatian: Xydalba sadrži natrij
English: • Viridans group streptococci (Streptococcus anginosus group only): Susceptible ≤ 0.125 mg/l; Resistant > 0.125 mg/l.
Croatian: • Viridans streptokoki (samo skupina Streptococcus anginosus): Osjetljiv ≤ 0,125 mg/l; Rezistentan > 0,125 mg/l.
English: is mediated by VanA, a genotype that results in modification of the target peptide in nascent cell wall.
Croatian: genotipom koji rezultira modifikacijom ciljnog peptida u nastajućoj staničnoj stijenci.
English: • The other ingredients are mannitol (E421), lactose monohydrate, hydrochloric acid and/or sodium hydroxide (for pH adjustment only).
Croatian: • Drugi sastojci su manitol (E421), laktoza hidrat, kloridna kiselina i/ili natrijev hidroksid (za podešavanje pH).
English: Before you are given this medicine, tell your doctor if you are pregnant, think you may be pregnant or are planning to have a baby.
Croatian: Ako ste trudni, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku za savjet prije nego primite ovaj lijek.
English: It is not known if Xydalba passes into breast milk in humans.
Croatian: Nije poznato prelazi li Xydalba u majčino mlijeko u ljudi.
English: Clinical drug-drug interaction studies with dalbavancin have not been conducted.
Croatian: Nisu provedena klinička ispitivanja interakcija lijekova s dalbavancinom.
English: Mixed infections
Croatian: Mješovite infekcije
English: The content of each vial must be reconstituted by slowly adding 25 ml of water for injections.
Croatian: Sadržaj jedne bočice mora se rekonstituirati polaganim dodavanjem 25 ml vode za injekcije.
English: Dalbavancin is not metabolised by CYP enzymes in vitro, therefore co-administered CYP inducers or inhibitors are unlikely to influence the pharmacokinetics of dalbavancin.
Croatian: Dalbavancin se ne metabolizira putem enzima CYP in vitro, stoga nije vjerojatno da istodobna primjena s induktorima ili inhibitorima CYP utječe na farmakokinetiku dalbavancina.
English: • Beta-haemolytic streptococci of Groups A, B, C, G: Susceptible ≤ 0.125 mg/l; Resistant > 0.125 mg/l,
Croatian: • Beta-hemolitički streptokoki skupine A, B, C, G: Osjetljiv ≤ 0,125 mg/l; Rezistentan > 0,125 mg/l,
English: A total of 10 paediatric patients with ages 12 to 16 years who had resolving infections were given single doses of either dalbavancin 1,000 mg (body weight ≥ 60 kg) or dalbavancin 15 mg/kg (body weight < 60 kg).
Croatian: Ukupno je 10 pedijatrijskih bolesnika u dobi od 12 do 16 godina s infekcijama u izlječenju, primilo jednokratnu dozu dalbavancina od 1000 mg (tjelesna težina ≥ 60 kg) ili dozu dalbavancina od 15 mg/kg (tjelesna težina < 60 kg).
English: Infection of the bowel has been reported as an uncommon side effect.
Croatian: Infekcija crijeva zabilježena je kao manje česta nuspojava.
English: Bactericidal activity against staphylococci in vitro is time-dependent at serum concentrations of dalbavancin similar to those obtained at the recommended dose in humans.
Croatian: Odnos farmakokinetika/farmakodinamika (PK/PD) Baktericidna aktivnost protiv stafilokoka in vitro ovisna je o vremenu pri serumskim koncentracijama dalbavancina sličnim onima dobivenim pri preporučenim dozama u ljudi.
English: Clostridioides (formerly Clostridium) difficile-associated diarrhoea
Croatian: Clostridioides (ranije Clostridium) difficile, oralna kandidijaza
English: In Phase 3 studies, patients have been administered single doses of up to 1,500 mg.
Croatian: ispitivanjima faze 3 bolesnici su primili jednokratne doze do 1500 mg.
English: Single-use 48 ml type I glass vial with an elastomeric stopper and a green flip off seal.
Croatian: I od 48 ml za jednokratnu uporabu, s elastomernim čepom i zelenim flip-off zatvaračem.
English: Koprska ulica 108 A SI-1000 Ljubljana Tel: +386 1 544 65 79 info@angelini.si
Croatian: Angelini Pharma d.o.o. Koprska ulica 108 A SI-1000 Ljubljana Tel: +386 1 544 65 79 info@angelini.si
English: Dalbavancin Plasma Concentrations versus time in a typical ABSSSI patient (simulation using population pharmacokinetic model) for both the single and the two-dose regimens.
Croatian: Slika 1. Koncentracije dalbavancina u plazmi u odnosu na vrijeme u tipičnog bolesnika s bakterijskom infekcijom kože i kožnih struktura (simulacija korištenjem populacijskog farmakokinetičkog modela) za režim jednokratnog doziranja i režim doziranja u dvije doze.
English: Xydalba may cause dizziness.
Croatian: Xydalba može uzrokovati omaglicu.
English: Adverse reactions are classified according to System Organ Class and frequency.
Croatian: Nuspojave su klasificirane prema klasifikaciji organskih sustava i učestalosti.
English: Description of selected adverse reactions
Croatian: Opis odabranih nuspojava Nuspojave skupine lijekova
English: In the major trials in ABSSSI the types of infections treated were confined to cellulitis/erysipelas, abscesses and wound infections only.
Croatian: U glavnim ispitivanjima akutnih bakterijskih infekcija kože i kožnih struktura, vrste liječenih infekcija bile su ograničene samo na celulitis/erizipel, apscese i infekcije rana.